Literature DB >> 27747069

The necessity of mediastinal lymph node resection for screen-diagnosed non-small cell lung cancer (NSCLC) manifesting as subsolid nodule.

Sukki Cho1.   

Abstract

Entities:  

Year:  2016        PMID： 27747069      PMCID： PMC5059235          DOI： 10.21037/jtd.2016.08.68

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

2.  Postoperative ischemic change in bronchial stumps after primary lung cancer resection.

Authors:  Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Atsushi Horiike; Fumiyoshi Ohyanagi; Makoto Nishio; Takeshi Horai; Yuichi Ishikawa
Journal:  Eur J Cardiothorac Surg       Date:  2006-05-26       Impact factor: 4.191

3.  Role of limited sublobar resection for early-stage lung cancer: steady progress.

Authors:  Hisao Asamura
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

4.  Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma.

Authors:  Morihito Okada; Haruhiko Nakayama; Sakae Okumura; Hiromitsu Daisaki; Shuji Adachi; Masahiro Yoshimura; Yoshihiro Miyata
Journal:  J Thorac Cardiovasc Surg       Date:  2011-03-25       Impact factor: 5.209

5.  Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial.

Authors:  J R Izbicki; O Thetter; M Habekost; O Karg; B Passlick; B Kubuschok; C Busch; K Haeussinger; W T Knoefel; K Pantel
Journal:  Br J Surg       Date:  1994-02       Impact factor: 6.939

6.  Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer?

Authors:  Christophe Doddoli; Adrian Aragon; Fabrice Barlesi; Bruno Chetaille; Stéphane Robitail; Roger Giudicelli; Pierre Fuentes; Pascal Thomas
Journal:  Eur J Cardiothorac Surg       Date:  2005-04       Impact factor: 4.191

Review 7.  Omission of mediastinal lymph node dissection in lung cancer: its techniques and diagnostic procedures.

Authors:  Hiroaki Nomori; Kazunori Iwatani; Hironori Kobayashi; Atsushi Mori; Shouichi Yoshioka
Journal:  Ann Thorac Cardiovasc Surg       Date:  2006-04       Impact factor: 1.520

8.  Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group.

Authors:  S M Keller; S Adak; H Wagner; D H Johnson
Journal:  Ann Thorac Surg       Date:  2000-08       Impact factor: 4.330

9.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.

Authors:  Gail E Darling; Mark S Allen; Paul A Decker; Karla Ballman; Richard A Malthaner; Richard I Inculet; David R Jones; Robert J McKenna; Rodney J Landreneau; Valerie W Rusch; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-03       Impact factor: 5.209

10.  Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer.

Authors:  Ajeet Gajra; Nancy Newman; Gary P Gamble; Leslie J Kohman; Stephen L Graziano
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544
  10 in total
  2 in total

1.  Should a therapeutic strategy be based on how the disease was diagnosed?

Authors:  Masaaki Sato
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

2.  Pathologic N0 Status in Clinical T1N0M0 Lung Adenocarcinoma is Predictable by the Solid Component Proportion with Quantitative CT Number Analysis.

Authors:  Meng Li; Ning Wu; Li Zhang; Wei Sun; Jianwei Wang; Lv Lv; Jiansong Ren; Dongmei Lin
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.